or 462

Nitecapone 是一个具有口服活性的、短效的儿茶酚-O-甲基转移酶(COMT)的抑制剂。它具有胃肠道保护和抗氧化活性，能够清除活性氧和一氧化氮，防止脂质过氧化。

TNG-462 是一种高效且选择性的 PRMT5 抑制剂，具有抗肿瘤活性和口服活性，主要用于治疗甲硫腺苷磷酸化酶（MTAP）缺失和 或甲硫腺苷（MTA）累积的癌症（如非小细胞肺癌、胰腺癌、膀胱癌和血液恶性肿瘤）。

DGN462 is an effective DNA alkylating agent with anti-tumor activity, as in acute myeloid leukemia (AML). DGN462 can be used as a cytotoxic component of antibody-drug conjugates (ADCs).

WR-S-462 是一种STAT3抑制剂，在体外能有效地阻碍STAT3的磷酸化及其生物学功能。该化合物对MDA-MB-231细胞的IC50为0.03 μM，并表现出对STAT3蛋白的强结合亲和力，其Kd为58 nM。WR-S-462 能抑制p-STAT3的核转位，特异性抑制MDA-MB-231细胞中p-STAT3Tyr705的表达，以及由STAT3调控的下游靶基因如Cyclin D1、Bcl-2和Bcl-xl的表达。此外，WR-S-462 有效抑制三阴性乳腺癌 (TNBC) 的生长和转移。

Sulfo-DGN462 sodium undergoes degradation to DGN462 when subjected to culture medium and plasma. DGN462, a highly effective DNA-alkylating agent, exhibits anti-tumor properties that are particularly active against acute myeloid leukemia (AML).

Sulfo-SPDB-DGN462为一种ADC活性连接剂，毒素DGN462通过可裂解的Sulfo-SPDB linker偶联形成。DGN462是一种DNA烷基化剂，对抗肿瘤（如急性髓系白血病[AML]）表现出有效性。

XM462 是一种二氢神经酰胺去饱和酶抑制剂，在体外产生混合型抑制（Ki=2 μM），且在体外和培养细胞中均有抑制作用，IC50值分别为8.2和0.78 μM。

Resolvin E2 (RvE2) is a member of the specialized pro-resolving mediator (SPM) family of bioactive lipids.1It is produced from eicosapentaenoic acidviaan 18-HEPE intermediate, which is formed by aspirin-acetylated COX-2-mediated oxidation of EPA, by 5-lipoxygenase (5-LO) in human polymorphonuclear (PMN) neutrophils.2,3RvE2 (20 ng/animal) inhibits increases in inflammatory exudate neutrophil infiltration in a mouse model of peritonitis induced by zymosan A .3Hepatic RvE2 levels are increased in mice fed normal chow, as well as in a mouse model of high-fat diet-induced non-alcoholic fatty liver disease (NAFLD), by dietary supplementation with EPA.4Plasma levels of RvE2 are increased by dietary supplementation with fish oil containing ω-3 polyunsaturated fatty acids (PUFAs) in patients with peripheral artery disease or chronic kidney disease.1,5,6 1.Chiang, N., and Serhan, C.N.Specialized pro-resolving mediator network: An update on production and actionsEssays Biochem.64(3)443-462(2020) 2.Tjonahen, E., Oh, S.F., Siegelman, J., et al.Resolvin E2: Identification and anti-inflammatory actions: Pivotal role of human 5-lipoxygenase in resolvin E series biosynthesisChemistry & Biology131193-1202(2006) 3.Sungwhan, F.O., Pillai, P.S., Recchiuti, A., et al.Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammationJ. Clin. Invest.121(2)569-581(2011) 4.Echeverría, F., Valenzuela, R., Espinosa, A., et al.Reduction of high-fat diet-induced liver proinflammatory state by eicosapentaenoic acid plus hydroxytyrosol supplementation: Involvement of resolvins RvE1/2 and RvD1/2J. Nutr. Biochem.6335-43(2019) 5.Ramirez, J.L., Gasper, W.J., Khetani, S.A., et al.Fish oil increases specialized pro-resolving lipid mediators in PAD (the OMEGA-PAD II trial)J. Surg. Res.238164-174(2019) 6.Barden, A.E., Shinde, S., Burke, V., et al.The effect of n-3 fatty acids and coenzyme Q10 supplementation on neutrophil leukotrienes, mediators of inflammation resolution and myeloperoxidase in chronic kidney diseaseProstaglandins Other Lipid Mediat.1361-8(2018)